Phase 3 First Patient Dosed

Innovate Biopharmaceuticals dosed the first patient in the their Phase 3 trial of Larazotide acetate a few days ago. The drug is designed to alleviate symptoms of accidental gluten exposure, however it is unclear if the drug will protect against the intestinal damage due to gluten exposure. The phase 3 trial will need over 600 volunteers and is expected to be completed at the end of 2021.

Review the study and decide if it is something you can do to help move science forward!!

Leave a Reply